2025年,全球制药行业迎来历史性转折点,GLP-1类减肥药彻底改写了市场格局。礼来凭借替尔泊肽以365亿美元年收入登顶“药王”宝座,诺和诺德司美格鲁肽以361亿美元紧随其后,两家巨头合计占据全球减肥药市场近八成分额。根据彭博行业研究预测,到2030年礼来市场份额有望达53%,诺和诺德降至33%,但市场总规模将突破1000亿美元,为其他参与者留下空间。值得关注的是,2025年的减肥药市场从诺和诺德...
Source Link2025年,全球制药行业迎来历史性转折点,GLP-1类减肥药彻底改写了市场格局。礼来凭借替尔泊肽以365亿美元年收入登顶“药王”宝座,诺和诺德司美格鲁肽以361亿美元紧随其后,两家巨头合计占据全球减肥药市场近八成分额。根据彭博行业研究预测,到2030年礼来市场份额有望达53%,诺和诺德降至33%,但市场总规模将突破1000亿美元,为其他参与者留下空间。值得关注的是,2025年的减肥药市场从诺和诺德...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.